Business Wire

SEOUL-VIOSYS

Share
Seoul Viosys: Through Air Purifier and Air Sterilizer Filters, Bacterial Growth and Leakage Occur

Seoul Viosys (“SVC”) (KOSDAQ: 092190), a global optical semiconductor company, conducted a test on air sterilization by air purifiers sold in the market. The test confirms that bacterial growth and its leakage occur through the filters. The Company announced filters in air purifiers and air sterilizers can cause viral infection and virus spread.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221229005046/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

[Figure 1] In-house bacterial culture measurement lab (left) in Seoul Viosys, and result of residual bacteria counting within filters (right) (Graphic: Business Wire)

The Company commissioned a research institute K, an internationally certified testing and research institute, to conduct a ‘test on bacterial residue count’ to check how many germs remain within filters. Air purifiers sold in the market were randomly selected and the filter contamination level was checked. For one gram of filter, an average of 70 CFU (colony forming unit) was confirmed, and for yeast and mold, more than 300 CFU per gram. These numbers are three times higher than the bacteria-permissible level, 100 CFU/g, in wet tissues under the current Cosmetics Act of Korea.

In general, air purifier filters need to be replaced, on a regular basis, every 6 months or every year, as the capture performance of filters is compromised due to suspended particles such as captured dust. According to a thesis on the survival period of harmful bacteria in filters (Survival of Microorganisms on HEPA Filters. James T. Walker et al., Applied Biosafety Vol. 16, No. 3, 2011), it has been confirmed that Staphylococcus epidermidis which causes vomiting, stomachache, and diarrhea can live up to five days in filters, and Bacillus atrophaeus can survive for more than 6 days up to 210 days at maximum.

The Bioresearch team of the Company checked bacterial residue inside filters, and then based on the outcome, the team also conducted a ‘virus filtration test (virus passage test).’ After spraying ‘Phi X 174’ virus which is similar to the Covid-19 virus in size and features at a chamber of 60 m3, air purifiers from Company A, B, and C were operated for 10 minutes, respectively. Then, the virus level was measured around the purifier’s outlet area, and virus level was confirmed at 0.005~0.01% compared to the sprayed virus concentration in the air. One virus can multiply up to 1 million to 100 million times at maximum in 5~6 hours, and even if air purifier filter is used, 10,000 viruses, amounting to 0.01%, may not be filtered and may disperse into the air. Usually, as a small number of viruses such as 1,000 flu (influenza) viruses and 10~100 Noroviruses can cause infection, a sterilization system to prevent any micro leakage is required. It has been measured that one droplet of a Covid-19 patient contains 100-1,000 viruses at maximum.

Young Ju Lee, CEO of Seoul Viosys Co., Ltd. said, “Through this test, it has been confirmed that as time goes by, filters can even work as a medium of bacteria growth, and viruses that pass the filter can spread the infection. Filters alone cannot prevent bacterial infection and sterilization will be the best way for disinfection.”

With its dedication to UV LED technology development for the last 20 years, the Company has developed a clean sterilization technology, ‘Violeds.’ As part of the activities to prevent the spread of infection through the air, in 2020, the Company has provided ‘air sterilizers’ for free in 300 SOHO business sites in Korea that combine filters with ‘Violeds’ technology, developed based on the investment of KRW one billion. According to a phone survey on its users in December 2022, 92% of respondents were found to be satisfied, and 83% said they would recommend the product to others, showing that the level of satisfaction with the product is quite high.

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “WICOP Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths range (200nm to 1600nm) including ultraviolet rays (UV), visible rays and infrared rays. It holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for strong sterilization and disinfection (UVC), skin regeneration (UVB), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add the advanced VCSEL technology which supports smartphone facial recognition and autonomous driving, and has started its mass production. In January 2020, it introduced a disruptive “WICOP Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/, YouTube, Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221229005046/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye